Welcome to our dedicated page for Curevac B.V. news (Ticker: CVAC), a resource for investors and traders seeking the latest updates and insights on Curevac B.V. stock.
CureVac N.V. develops messenger RNA medicines for human medicine, with programs spanning cancer immunotherapy, prophylactic vaccines, and therapies designed to enable the body to produce therapeutic proteins. The company applies mRNA technology with omics and computational tools to off-the-shelf and personalized precision immunotherapy candidates, including oncology programs such as CVHNLC for squamous non-small cell lung cancer and CVGBM for glioblastoma.
CureVac news commonly covers operating and financial results, clinical and regulatory disclosures, patent litigation involving mRNA technologies such as split poly-A tail technology, and shareholder meeting outcomes. Updates also address governance votes, board and auditor matters, material agreements, capital-structure disclosures, and other corporate-status developments.
CureVac (Nasdaq:CVAC) announced that shareholders at its Extraordinary General Meeting approved all proposals related to BioNTech's public exchange offer, with approvals above 99.16% of votes cast.
Valid votes represented 70.52% of registered share capital. The Offer expires Dec 3, 2025 at 9:00 AM ET; shareholders are advised to tender by Dec 2, 2025 at 6:00 PM ET due to operational deadlines. Approved items include the legal downstream merger, post-offer reorganization steps, releases from liability for directors, and conditional appointments of Ramón Zapata Gomez and three supervisory directors.
CureVac (Nasdaq:CVAC) reported Q3 and nine-month 2025 results and business updates on April 14, 2026, highlighting progress on the planned BioNTech transaction and clinical programs.
Key figures: cash €416.1m (Sep 30, 2025), revenues €54.1m Q3 and €56.3m YTD, operating profit impacted by a $420m one-time U.S. settlement effect, and expected cash runway into 2028.
CureVac (NASDAQ:CVAC) reported Q2 and H1 2025 financial results and significant business developments. The company entered into a definitive Purchase Agreement with BioNTech for acquisition of all CureVac shares. Additionally, CureVac resolved patent litigation with Pfizer/BioNTech, receiving $740 million plus royalties for COVID-19 vaccine sales.
Financial highlights include cash position of €392.7 million as of June 30, 2025, with runway extended into 2028. Revenues decreased to €2.1 million in H1 2025, down 92% year-over-year. Operating loss improved to €116.5 million for H1 2025.
In clinical developments, CureVac received CTA clearance from EMA for CVHNLC cancer immunotherapy targeting squamous non-small cell lung cancer, while glioblastoma trial data remains on track for H2 2025.
CureVac (NASDAQ:CVAC), a pioneering mRNA-focused biotech company, announced the results of its Annual General Meeting. Shareholders approved all proposals, including key management changes. Axel Sven Malkomes was appointed to the Management Board, while Jean Stéphenne, Debra Barker, Craig A. Tooman, and Klaus Schollmeier were reappointed to the Supervisory Board. Mehdi Shahidi joined as a new Supervisory Board member. Additionally, KPMG Accountants N.V. was reappointed as external auditors for the financial year 2026.
CureVac (NASDAQ:CVAC) reported its Q4 and full-year 2024 financial results, marking a year of strategic transformation. The company completed enrollment for Part B of its Phase 1 glioblastoma study, with data readout expected in H2 2025. The FDA cleared their sqNSCLC Phase 1 study to begin in H2 2025.
Key financial highlights include a strong cash position of €481.7 million as of December 31, 2024, with runway extended into 2028. Full-year 2024 revenues reached €535.2 million, including a €400 million upfront payment from GSK licensing agreement. The company reported an operating profit of €177.7 million for 2024.
Notable developments include a positive ruling from the European Patent Office confirming CureVac's patent validity in proceedings against BioNTech SE, with a U.S. jury trial postponed to September 2025. The company also received a €10 million milestone payment for initiating Phase 1 of a seasonal influenza/COVID-19 combination vaccine study with GSK.
CureVac (Nasdaq: CVAC), a global biotech company focused on developing mRNA-based transformative medicines, has scheduled its Fourth Quarter and Full-Year 2024 Financial Results announcement for April 10, 2025.
The company will host a conference call and webcast at 3 p.m. CET / 9 a.m. EST on the same day. Investors and interested parties can access the event through U.S. Toll-Free (+1-877-407-0989), International (+1-201-389-0921), and German landline (0800-182-0040) or cell phone (0800-184-4713) numbers.
Presentation slides will be available before the webcast through CureVac's website newsroom section, with a replay available afterward.
CureVac (Nasdaq: CVAC) has received FDA clearance for its Investigational New Drug (IND) application to begin a Phase 1 clinical trial of CVHNLC in squamous non-small cell lung cancer (sqNSCLC) patients. CVHNLC is an mRNA-based precision immunotherapy encoding eight tumor-associated antigens.
The trial will evaluate CVHNLC in combination with pembrolizumab, featuring two parts:
- Part A: dose-escalation study (100μg to 400μg) as first-line maintenance treatment
- Part B: optional dose expansion testing CVHNLC with first-line chemotherapy and pembrolizumab
Primary endpoints include dose-limiting toxicities and treatment-related adverse events, while secondary endpoints cover overall response rate, progression-free survival, and disease control rate. Patient treatment is expected to begin in the second half of 2025, with additional oncology candidates planned for clinical trials in 2026.
CureVac (NASDAQ:CVAC) has achieved a significant legal victory as the European Patent Office (EPO) largely dismissed BioNTech SE's opposition to CureVac's patent EP 3 708 668 B1, maintaining it in amended form. The patent covers CureVac's split poly-A tail technology, a foundational invention that enhances medical efficacy by improving protein expression in mRNA constructs.
This ruling marks a important milestone in the broader patent litigation between CureVac and BioNTech in Germany, which involves six intellectual property rights. An infringement hearing is scheduled for July 1, 2025, at the Regional Court Düsseldorf. If the court rules in CureVac's favor regarding infringement, it will trigger proceedings to assess damages.